There is an enormous medication adherence problem in the United States, and millions of people could benefit from cognitive therapy, and technology can help.
There is an enormous medication adherence problem in the United States, and millions of people could benefit from cognitive therapy, and technology can help, explained Thomas Morrow, MD, chief medical officer of NextIT, board member of The American Journal of Managed Care and contributor to AJMC.com.
During the keynote presentation on Friday at the Fall Managed Care Forum 2015, presented by the NAMCP Medical Directors Institute, the American Association of Integrated Healthcare Delivery Systems, and the American Association of Managed Care Nurses, Dr Morrow discussed why people fail to take good care of themselves, why current approaches to address the issue aren’t working, and how a virtual health assistant (VHA) can be the solution.
Health is the result of a complex interaction of both good and bad influences on a person’s health, including genetics, education, socio-economic factors, cultural influences, interpersonal determinants, age and life-stage, and societal influences. While some factors cannot be changed, others can.
“Behaviors are really key to healthcare and health outcomes, and we don’t spend any time on them,” he said.
There is a long list of why current approaches do not work, such as forgetfulness, financial considerations, and time constraints, and ways to engage patients better can be lacking. While office visits are the most effective approach, this is costly and time consuming. More affordable options like text messaging can be lacking since there usually is not another person at the other end and the technology lacks intelligence to understand the response.
“When you start using virtual health technology, the cost is almost nothing,” Dr Morrow said. “It’s the cost to run the servers once they’re built.”
VHAs are the future and the industry is heading there quickly, he added. They are trained to know clinical guidelines, handle adverse events, operate within medical-legal boundaries, reflect branding, and get more intelligent over time.
Dr Morrow said that while many people assume the type of technology he is talking about—think the movie Her or HAL 9000 in 2001: A Space Odyssey—won’t actually happen and be implemented in their lifetime, but it’s already here.
There are 2 major concerns with the use of VHAs: will patients embrace the digital touch? Can a VHA facilitate better health outcomes? The answer to both, according to studies that have already been done, is “yes,” said Dr Morrow.
Studies have shown that it doesn’t matter what demographic or what level of computer literacy, VHAs had positive results. In fact, patients prefer a virtual agent over a human almost three-fourths of the time with virtual agents increasing the patient’s willingness to disclose truthful information.
One study assessed how patients felt about the VHA after using it and found that one a scale of 1 to 5 (1 being not at all and 5 being very much), patients felt the VHA cared about them (4.24), trusted the VHA (4.44), liked the VHA (4.3) and were very satisfied (4.49).
With a number of companies working in this space now, it is quickly becoming its own industry. Dr Morrow said there aren’t any other scalable, viable, affordable, and acceptable options for improving behavioral and adherence with the same potential of a VHA.
“This will be our next big industry,” he said. “It will be digital health.”
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
Inside the Center's MDD Value Model and Its Use of Dynamic Pricing
May 13th 2025Larragem Raines, MS, of the Center for Innovation & Value Research, discusses the organization's major depressive disorder (MDD) open-source value model, dynamic pricing, and the future role of artificial intelligence in care.
Listen
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More